DE60042342D1 - - Google Patents

Info

Publication number
DE60042342D1
DE60042342D1 DE60042342T DE60042342T DE60042342D1 DE 60042342 D1 DE60042342 D1 DE 60042342D1 DE 60042342 T DE60042342 T DE 60042342T DE 60042342 T DE60042342 T DE 60042342T DE 60042342 D1 DE60042342 D1 DE 60042342D1
Authority
DE
Germany
Prior art keywords
methods
human
hama
antibodies
samples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60042342T
Other languages
English (en)
Inventor
Joe Buechler
Gunars Valkirs
Jeff Gray
Nils Lonberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Genpharm International Inc
Original Assignee
Genpharm International Inc
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23811375&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60042342(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genpharm International Inc, Biosite Inc filed Critical Genpharm International Inc
Application granted granted Critical
Publication of DE60042342D1 publication Critical patent/DE60042342D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
DE60042342T 1999-12-06 2000-12-06 Revoked DE60042342D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/456,090 US6680209B1 (en) 1999-12-06 1999-12-06 Human antibodies as diagnostic reagents
PCT/US2000/033042 WO2001040306A1 (en) 1999-12-06 2000-12-06 Human antibodies as detection reagents

Publications (1)

Publication Number Publication Date
DE60042342D1 true DE60042342D1 (de) 2009-07-16

Family

ID=23811375

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042342T Revoked DE60042342D1 (de) 1999-12-06 2000-12-06

Country Status (9)

Country Link
US (3) US6680209B1 (de)
EP (1) EP1237926B1 (de)
JP (1) JP2003530543A (de)
AT (1) ATE432947T1 (de)
AU (1) AU781736B2 (de)
CA (1) CA2392729A1 (de)
DE (1) DE60042342D1 (de)
GB (1) GB2374415B (de)
WO (1) WO2001040306A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
JP2005533486A (ja) * 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
EP1504034B1 (de) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
CA2496741A1 (en) * 2002-08-28 2004-04-29 Bionexus Ventures L.L.C. Screening compound libraries using an optical fiber array device capable of simultaneously performing multiple functional assays
EP1590364B1 (de) * 2002-12-16 2011-10-05 Genmab A/S Humane monoklonale antikörper gegen interleukin 8 (il-8)
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
RS54160B1 (sr) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Protein koji se vezuje za nogo receptor
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2572193A1 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving oligodendrocytes with sp35 based agents
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
EP1817341A2 (de) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Veränderte antikörper und immunkonjugate
US7396689B2 (en) * 2005-02-04 2008-07-08 Decision Biomarkers Incorporated Method of adjusting the working range of a multi-analyte assay
CA2605964A1 (en) 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
WO2007084321A2 (en) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
CA2652538C (en) * 2006-05-19 2016-06-28 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP5553615B2 (ja) * 2007-03-01 2014-07-16 アボット・ラボラトリーズ プロゾーン現象の低減を示すイムノアッセイ
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
US20090203038A1 (en) * 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
WO2009125394A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
EP2297200A1 (de) * 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti-influenza-antikörper und anwendungen davon
WO2009125381A1 (en) * 2008-04-10 2009-10-15 Objet Geometries Ltd. System and method for three dimensional model printing
SE533515C2 (sv) 2008-04-16 2010-10-12 Aamic Ab Analysförfarande för samtidig analys av flera analyter
EP2309264A4 (de) * 2008-06-06 2011-11-23 Univ Toyama Nat Univ Corp Grippevirusnachweisvorrichtung
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011022472A2 (en) * 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
RU2571489C2 (ru) 2009-10-26 2015-12-20 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
EP2523976B1 (de) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarker für immunmodulatorische effekte bei mit antikörpern gegen cd200 behandelten patienten
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
BR112013009376A2 (pt) 2010-10-18 2016-07-26 Nestec Sa métodos para determinar isótipos de anticorpos antifármacos
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
DK3228631T3 (da) * 2011-06-13 2020-09-28 Tla Targeted Immunotherapies Ab Behandling af respiratoriske tilstande
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
US9220733B2 (en) 2012-03-19 2015-12-29 The Regents Of The University Of California Solubilization of antigen components for removal from tissues
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2014085687A1 (en) 2012-11-28 2014-06-05 Abwiz Bio, Inc. Preparation of gene-specific templates for the use in single primer amplification
US20140212987A1 (en) * 2013-01-30 2014-07-31 Siemens Healthcare Diagnostics Inc. Signal Ratio in Assay Calibrators
EP3004882B1 (de) * 2013-06-06 2018-03-21 Koninklijke Philips N.V. Reagenzien, verfahren und vorrichtungen zur verhinderung der aggregation bei partikelbasierten tests für den nachweis von multimeren zielmolekülen
BR112017011545A2 (pt) 2014-12-05 2018-03-13 Nestec Sa ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN108064241A (zh) * 2015-04-17 2018-05-22 阿尔萨尼斯生物科学有限责任公司 针对金黄色葡萄球菌的免疫球蛋白结合蛋白的抗体
US11899020B2 (en) 2017-03-31 2024-02-13 The Regents Of The University Of California Shotgun proteomic antigen identification
BR112020013144A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer
BR112021022405A2 (pt) * 2019-05-09 2022-04-19 Merus Nv Domínios variantes para multimerização de proteínas e separação das mesmas
WO2021154993A1 (en) * 2020-01-28 2021-08-05 University Of Southern California Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
DE3269567D1 (en) * 1981-04-29 1986-04-10 Ciba Geigy Ag New devices and kits for immunological analysis
US4514505A (en) * 1982-05-21 1985-04-30 The Trustees Of Columbia University In The City Of New York Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DK169582B1 (da) 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5914241A (en) 1993-01-19 1999-06-22 Biosite Diagnostics, Inc. Assays and kits for detecting analytes in the presence of cross-reacting substances
WO1994026787A1 (en) 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
ATE405679T1 (de) * 1993-10-19 2008-09-15 Scripps Research Inst Synthetische humane neutralisierende monoklonale antikörper gegen hiv
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
JPH07260786A (ja) * 1994-03-18 1995-10-13 Tosoh Corp ヒト由来一定領域を有する抗体を使用する免疫測定方法
WO1995033992A1 (en) * 1994-06-09 1995-12-14 Bar-Ilan University Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP2002514919A (ja) 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド 多価ライブラリーおよびポリクローナルライブラリー
EP0934953A2 (de) 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Komplexspezifische Antikörper, Verfahren zur Herstellung und deren Verwendungen
US5939807A (en) 1997-12-16 1999-08-17 Reliance Electric Industrial Company Cap mounted drive for a brushless DC motor
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies

Also Published As

Publication number Publication date
GB2374415B (en) 2004-12-29
WO2001040306A1 (en) 2001-06-07
US20080039338A1 (en) 2008-02-14
GB0215302D0 (en) 2002-08-14
CA2392729A1 (en) 2001-06-07
GB2374415A (en) 2002-10-16
US7189515B2 (en) 2007-03-13
US6680209B1 (en) 2004-01-20
EP1237926A1 (de) 2002-09-11
EP1237926A4 (de) 2006-04-12
US20030165993A1 (en) 2003-09-04
WO2001040306A9 (en) 2002-05-30
AU781736B2 (en) 2005-06-09
EP1237926B1 (de) 2009-06-03
AU2063001A (en) 2001-06-12
ATE432947T1 (de) 2009-06-15
JP2003530543A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
DE60042342D1 (de)
IL146660A0 (en) Method for separating cells using immunorosettes
AU2002304640A1 (en) Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
WO2005003767A3 (en) Elemental analysis of tagged biologically active materials
TW370614B (en) Oligomerized antibodies, method of immunological determination using the same and reagent kit comprising the same
EP0957365A4 (de) Fluoreszierende polarisation
PL350318A1 (en) Protein isolation and analysis
DK1098658T3 (da) Manipulerede proteiner til detektering af analytter
WO1999022242A3 (en) Measurement of glycated hemoglobin
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
KR960029789A (ko) 생체내 물질의 면역학적 분석용 키트 및 면역학적 분석 방법
DK0544869T3 (da) Immunologisk analysemetode til bestemmelse af antistoffer i biologiske væsker, og et analytisk kit t il gennemførelse heraf
ATE310956T1 (de) Festphasenverfahren und testsatz zur antigen- und antikörperprüfung in der blutgruppen-serologie
AU629886B2 (en) Diagnostic test using chimeric antibodies
WO2001020326A3 (en) Materials and methods for the determination of an analyte
WO2001002853A3 (en) DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
HUP9800225A2 (hu) Eljárás és vegyületek analitok meghatározására remanenciaméréssel és ezek alkalmazásai
WO1998029726A3 (en) Method of detecting and determining the concentration of total troponin i in a biological sample
EP0387027A3 (de) Methode und Reagenz zur Diagnose von Endometriose
WO2002071061A3 (en) Quantitative detection of the conformation changes of p-glycoprotein
AU2001250470A1 (en) Novel antibodies specifically identifying inactive psa, and uses thereof
DE69308825T2 (de) Verfahren zur bestimmung von autoantikörpern in biologischen flüssigkeiten
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation